News

News

Media Contact

    • 28 November 2017
    • Rosen Comments on FDA Commissioner’s Remarks

    • Partner David Rosen is quoted in a Pink Sheet article, “Gottlieb’s Complex Generics Remarks Could Signal (Some) Increased Flexibility,” about FDA Commissioner Scott Gottlieb’s remarks on generic copies of products with drug and device constituent parts at an internal FDA event for agency scientists and researchers.
    • 14 July 2017
    • Rosen Comments on FDA User Fee Legislation

    • In Modern Healthcare’s article, “House Passes Bipartisan FDA User Fee Bill,” Partner David Rosen discussed the impact of new legislation passed in the House of Representatives that reauthorizes the FDA’s ability to collect user fees from drug and device makers.
    • 15 May 2018
    • Rosen Comments on Proposed Changes in FDA Drug-Device Rules

    • Partner David Rosen is quoted in a Bloomberg Law article, “Drug-Device Rules Could Give FDA Leg Up in Industry Fights,” about the FDA’s plan to revamp its rules on how to deal with overlapping drug, device and biologic products.
    • 22 September 2016
    • Rosen Quoted on FDA Requirements for Drug Shelf Life

    • Partner David Rosen was quoted in a Modern Healthcare article, “Extending EpiPen Shelf Life Could be a Relief for Patients, Costly for Mylan,” on September 22, 2016.
    • 24 October 2016
    • Rosen Quoted on Obstacles to Generic EpiPen

    • Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106.
    Filters applied:
    Search phrase entered: